[go: up one dir, main page]

UA109420C2 - PHARMACEUTICAL COMPOSITION INCLUDING GLP-1 AGONIST, INSULIN AND METHIONINE - Google Patents

PHARMACEUTICAL COMPOSITION INCLUDING GLP-1 AGONIST, INSULIN AND METHIONINE

Info

Publication number
UA109420C2
UA109420C2 UAA201207165A UAA201207165A UA109420C2 UA 109420 C2 UA109420 C2 UA 109420C2 UA A201207165 A UAA201207165 A UA A201207165A UA A201207165 A UAA201207165 A UA A201207165A UA 109420 C2 UA109420 C2 UA 109420C2
Authority
UA
Ukraine
Prior art keywords
agonist
methionine
insulin
pharmaceutical composition
composition including
Prior art date
Application number
UAA201207165A
Other languages
Russian (ru)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/067250 external-priority patent/WO2011058083A1/en
Publication of UA109420C2 publication Critical patent/UA109420C2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується рідкої композиції, що включає агоніст GLP-1 (desProексендин-4(1-39)-LyS-NH) і/або його фармакологічно прийнятну сіль, інсулін (Gly(A21)-Arg(B31)-Arg(B32)-iнcyлiн людини) і/або його фармакологічно прийнятну сіль і, необов'язково, щонайменше одну фармацевтично прийнятну допоміжну речовину, де дана композиція містить L-метіонін та має значення pH від 3,5 до 4,5.The invention relates to a liquid composition comprising the GLP-1 agonist (desProexendin-4 (1-39) -LyS-NH) and / or its pharmacologically acceptable salt, insulin (Gly (A21) -Arg (B31) -Arg (B32) - human incyline) and / or its pharmacologically acceptable salt and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition contains L-methionine and has a pH of from 3.5 to 4.5.

UAA201207165A 2009-11-13 2010-11-11 PHARMACEUTICAL COMPOSITION INCLUDING GLP-1 AGONIST, INSULIN AND METHIONINE UA109420C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009052831 2009-11-13
PCT/EP2010/067250 WO2011058083A1 (en) 2009-11-13 2010-11-11 Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine

Publications (1)

Publication Number Publication Date
UA109420C2 true UA109420C2 (en) 2015-08-25

Family

ID=54772073

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201207165A UA109420C2 (en) 2009-11-13 2010-11-11 PHARMACEUTICAL COMPOSITION INCLUDING GLP-1 AGONIST, INSULIN AND METHIONINE

Country Status (1)

Country Link
UA (1) UA109420C2 (en)

Similar Documents

Publication Publication Date Title
NZ599848A (en) Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
TN2012000215A1 (en) Pharmaceutical compositions comprising a g l p -1 agonist and methionine
CL2012002031A1 (en) Pharmaceutical composition containing at least one fgf-21 compound (fibroblast growth factor 21) and at least one glp-1r agonist (glucagon-like peptide 1 receptor); and its use to prepare a medicament for the treatment of at least one metabolic syndrome and / or atherosclerosis in a patient.
MA32703B1 (en) A combination of insulin and glp-1 agonist
CY1119582T1 (en) HYDRAULIC INSULIN PREPARATIONS CONTAINING Methionine
PH12015500194A1 (en) Fusion proteins for treating a metabolic syndrome
CL2009000173A1 (en) Compounds derived from urea-tetrahydroxyquinoxaline; preparation procedure; intermediate compounds; pharmaceutical composition; and use for the treatment and prevention of obesity and diabetes, insulin resistance, metabolic syndrome, among others.
WO2009086400A3 (en) Recombinant vwf formulations
CL2008000198A1 (en) COMPOUNDS DERIVED FROM AZACICLOALCANOS, INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF SICK DISEASES AS TYPE 2 DIABETES, LIPID DISORDER, OBESITY AND ATEROSCLEROSIS.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
CL2007003440A1 (en) COMPOUNDS DERIVED FROM AZACICLOALCANOS, INHIBITORS FROM ESTEAROIL-COENZIMA TO DELTA-9 DESATURASA; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF DISEASES SUCH AS TYPE 2 DIABETES, INSULIN RESISTANCE, LIPID DISORDERS, OBESIDA
CL2011003173A1 (en) Glucagon analog, gip and glp-1 agonist; dimer comprising the glucagon analog; conjugated to the analog; composition comprising said analog; use to prepare a medicine to treat diabetes, reduce weight gain, or induce weight loss.
CY1117603T1 (en) LIXISENATIDE AS AN ADDITION TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES
WO2009111611A3 (en) Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
DE602007002553D1 (en) THEIR USE FOR THE PREPARATION OF A THERAPEUTIC AND / OR PROPHYLACTICALLY ACTIVE PHARMACEUTICAL COMPOSITION
NZ609596A (en) Cyclohexane derivative compound
IN2012DN00977A (en)
WO2008116913A3 (en) Peptide compounds with transient biodegradable pegylation
UA109420C2 (en) PHARMACEUTICAL COMPOSITION INCLUDING GLP-1 AGONIST, INSULIN AND METHIONINE
AR074470A1 (en) AMIDA COMPOUND OF THE CYCLOPROPANOCARBOXYL ACID, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES
UA106478C2 (en) Combination of insulin and glp-1 agonist
EA201070251A1 (en) Drug in the form of a powder for nasal delivery of ascorbic acid to reduce the toxicity with regard to the spring tissue induced by apomorphine
WO2015015509A3 (en) Ulmoside-a: useful for prevention or cure of metabolic diseases
SE0402640D0 (en) Pharmaceutical use